No Data
Healthcare Up as Traders Rotate to Less Inflation-Sensitive Sectors -- Health Care Roundup
Are Healthcare Services Group, Inc.'s (NASDAQ:HCSG) Mixed Financials Driving The Negative Sentiment?
UBS Group: Maintains a "Buy" rating on JD HEALTH, raises the Target Price to 45 HKD.
UBS Group released a Research Report stating that it maintains a 'Buy' rating on JD HEALTH (06618), with the Target Price raised from HKD 35.2 to HKD 45. The bank has raised its revenue forecasts for 2025 to 2027 by 3% to 4%, expecting a compound annual growth rate of 15% from 2024 to 2026. The bank believes the market has overlooked JD HEALTH's revenue growth potential. UBS Group has increased its revenue forecasts for 2025 to 2027 by 3% to 4%, reflecting the accelerated penetration of online Pharmaceuticals and market share expansion. The bank has raised its valuation basis, adjusting the forecasted 2026 P/S ratio from 1.4 times to 1.7 times (averaged in the Internet Sector.
Insider Sale: SVP & Chief Accounting Officer of $HCSG Sells 1,744 Shares
Implied Volatility Surging for Healthcare Services Group (HCSG) Stock Options
Healthcare Services Group Faces Financial Risks Amid Growing ESG Regulatory Demands
Why Investors Shouldn't Be Surprised By Healthcare Services Group, Inc.'s (NASDAQ:HCSG) 28% Share Price Surge
